1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%

 
• By Dean Rudge

Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.

business growth
Stada's Generics And Specialty Sales Grew • Source: Alamy

Rolling out its Oyavas (bevacizumab) biosimilar to Roche’s Avastin in Europe, alongside launching complex generics such as Jevtana (cabazitaxel) and Faslodex (fulvestrant), helped bring about 9% sales growth to €638.7m ($701.7m) for STADA Arzneimittel AG’s newly-organized Specialty segment in 2021.

Meanwhile, the privately-held generics giant has disclosed, Stada’s total Generics sales increased by 2% to €1.326

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

 
• By Dean Rudge

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

More from Business